RT Journal Article
T1 Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis.
A1 Pereson, Matías J
A1 Amaya, Lucas
A1 Neukam, Karin
A1 Baré, Patricia
A1 Echegoyen, Natalia
A1 Badano, María Noel
A1 Lucero, Alicia
A1 Martelli, Antonella
A1 Garcia, Gabriel H
A1 Videla, Cristina
A1 Martínez, Alfredo P
A1 Di Lello, Federico A
K1 Gam-COVID-Vac
K1 Heterologous scheme
K1 SARS-CoV-2
K1 Vaccine
K1 mRNA-1273
AB To compare the homologous prime-boost vaccination scheme of Gam-COVID-Vac (Sputnik V (SpV)) to its heterologous combination with mRNA-1273 (Moderna (Mod)) vaccine. SARS-CoV-2 anti-spike (S)-receptor binding domain (RBD) IgG concentration was assessed three to seven weeks after complete vaccination. Reactogenicity was evaluated by declared side events and medical assistance required until day 7 post boost. Of 190 participants enrolled, 105 received homologous SpV/SpV and the remaining heterologous SpV/Mod vaccination scheme, respectively. Median (interquartile range (IQR)) age was 54 (37-63) years, 132 out of 190 (69.5%) were female, and 46 out of 190 (24.2%) individuals had a prior confirmed COVID-19. Anti-S-RBD IgG median (IQR) titers were significantly higher for SpV/Mod (2511 (1476-3992) binding antibody units (BAU)/mL) than for SpV/SpV (582 (209-1609) BAU/mL; p  The heterologous SpV/Mod combination against SARS-CoV-2 is well tolerated and significantly increases humoral immune response as compared to the homologous SpV/SpV immunization.
YR 2022
FD 2022-05-17
LK http://hdl.handle.net/10668/22131
UL http://hdl.handle.net/10668/22131
LA en
DS RISalud
RD Apr 12, 2025